Navigation Links
MetaChip provides quick, efficient toxicity screening of potential drugs

A large, multisite trial designed to examine the safety and preliminary effectiveness of two candidate topical microbicides to prevent HIV infection has opened to volunteer enrollment. The trial, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, represents a partnership among various research institutions in Africa and the United States.

Although no licensed microbicides are available to the public currently, scientists hope these agents--designed to be applied to the surface of the vagina to prevent sexually transmitted infections (STIs)--will one day be a key tool in the fight against HIV/AIDS.

Women make up nearly half of all people living with HIV worldwide. "The majority of new cases of HIV infection in women result from heterosexual intercourse, but women may not always be able to insist that their male partners use measures to prevent HIV transmission," notes NIAID Director Anthony S. Fauci, M.D. "If effective, microbicides would be a valuable woman-controlled means of slowing the pace of the HIV/AIDS epidemic," Dr. Fauci adds.

The first volunteers were enrolled this week at sites in Durban, South Africa, and at the University of Pennsylvania in Philadelphia. Enrollment will begin shortly at sites in four additional African countries--Malawi, Tanzania, Zimbabwe and Zambia. Approximately 3,220 women will be enrolled in the trial, which is expected to last approximately 30 months.

"This is the first microbicide safety and effectiveness trial of this magnitude to be conducted by NIAID," says Roberta J. Black, Ph.D., Topical Microbicide Team Leader in NIAID's Division of AIDS. "It is a critical trial evaluating two topical microbicides with differing mechanisms of action," she adds.

The microbicides to be tested are PRO 2000 and BufferGel. Produced by Indevus Pharmaceuticals, Lexington, MA, PRO 2000 has shown activity against HIV and other STIs in both laboratory and animal testing. It is believed to act by inhibiting the entry of HIV and other pathogens into body cells. BufferGel, a product of ReProtect, Inc., Baltimore, MD, boosts the natural acidity of the vagina in the presence of seminal fluid that neutralizes the vaginal environment. An acidic environment inactivates HIV as well as other pathogens.

Each woman in the trial will be placed at random into one of four equally sized groups. One group will use BufferGel before each act of sexual intercourse, one group will use PRO 2000, one group will use a placebo gel, and the final group will not use any gel. In addition, all participants will receive condoms and extensive prevention counseling at each clinic visit.

The trial is one of numerous studies conducted through NIH's HIV Prevention Trials Network (HPTN), which is funded by NIAID, the National Institute of Child Health and Human Development, the National Institute on Drug Abuse and the National Institute of Mental Health. More information about this study (HPTN 035) is available at www.hptn.org/index.htm. The protocol chair of the study is Salim Abdool Karim, MBChB, Ph.D., of the University of KwaZulu-Natal in Durban, South Africa.


'"/>

Source:


Related biology news :

1. NYU and MSKCC research provides model for understanding chemically induced cancer initiation
2. Nature provides inspiration for important new adhesive
3. New plant DNA libraries provides massive boost to worlds plant researchers
4. NASA satellite data provides rapid analysis of Amazon deforestation
5. Study provides insight into cellular defenses against genetic mutation
6. Customized gene chip provides rapid detection of genetic changes in childrens cancer
7. Vaccine provides 100 percent protection against avian flu virus in animal study
8. New hybrid virus provides targeted molecular imaging of cancer
9. Ancient DNA provides clues to the evolution of social behavior
10. Brittlestar provides new model for stem cell research
11. Use of amino acid supplement following a heart attack provides no benefit, may be harmful
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/18/2018)... ... December 18, 2018 , ... CP Merritt is a national champion ... for many years however in 2006, he had a medical setback that caused him ... that he suffered from cartilage degeneration in his right rear fetlock. Such an ...
(Date:12/13/2018)... ... December 13, 2018 , ... Study Protocol Summary of ... (with Ethical e-CRF®): IGA first assessment performed at the site., 3 - Three photos ... Staff Controls Photo anonymization in BOX., 5 - Photos moved to eAdjudication® and submitted ...
(Date:12/13/2018)... ... December 12, 2018 , ... Royal Biologics, an ... has announced the launch of Maxx-Cell, the world's most advanced bone marrow aspiration ... aspirating a patients autologous bone marrow cells. Maxx™-Cell however does not require centrifugation ...
Breaking Biology News(10 mins):
(Date:1/10/2019)... ... ... was adopted from a local shelter when he was around two years old. According ... weeks after he was adopted, he tore his right cruciate ligament. Though he had ... such a traumatic injury. , Sure enough, when Rascal was about nine years old, he ...
(Date:1/8/2019)... DENVER (PRWEB) , ... January 07, 2019 , ... ... comprised of its members into Noninvasix. This represents the second investment AngelMD has ... neonatal mortality and morbidity, Noninvasix is developing a patient monitor to directly, accurately, ...
(Date:1/4/2019)... TRIANGLE PARK, N.C. (PRWEB) , ... January 04, ... ... consulting organization, is pleased to welcome Ted Hoffman to the firm. Ted will ... 20 years of experience working in and providing consulting services to the pharmaceutical ...
(Date:1/4/2019)... ... January 03, 2019 , ... Calidi Biotherapeutics, ... cancer, today announced the founding of a scientific and medical advisory board (SMAB). ... key leaders in the Immuno-Oncology field. The founding members of Calidi Biotherapeutics SMAB ...
Breaking Biology Technology: